72results about How to "Increase expression" patented technology

The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Lepidoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic acid of the embodiments. These compositions find use in methods for controlling pests, especially plant pests.

The present invention provides for a method of producing one or more fatty acid derived dicarboxylic acids in a genetically modified host cell which does not naturally produce the one or more derived fatty acid derived dicarboxylic acids. The invention provides for the biosynthesis of dicarboxylic acid ranging in length from C3 to C26. The host cell can be further modified to increase fatty acid production or export of the desired fatty acid derived compound, and / or decrease fatty acid storage or metabolism.

A gene regulatory system controls biomarker, gene therapy or endogenous gene expression by emitting one or more forms of energy that regulate gene expression. The system may include a sensor to sense a signal indicative of a need for therapy. The regulation of gene expression is controlled based on the sensed signal and / or a user command. In one embodiment, the system delivers one or more electrical therapies in conjunction with controlling gene therapy or endogenous gene expression.

The present invention relates to compositions and methods for treating, preventing and improving the condition and / or aesthetic appearance of skin, particularly, treating, preventing, ameliorating, reducing and / or eliminating fine lines and / or wrinkles of skin, where the compositions include active agents which increase expression levels of genes associated with the dermatological signs of aging. The compositions of the invention are topically applied to the skin, or are delivered by directed means to a site in need thereof, once daily in an amount effective in improving the condition and / or aesthetic appearance of skin.

The present invention relates to methods to treat or prevent cancers in a subject, in particular the present invention relates to a method of treating and / or preventing cancer comprising targeting cancer stem cells by administering miRNAs which have reduced expression or are lacking in the cancer stem cells. In some embodiments, the miRNAs that are reduced or lacking in cancer stem cells are let-7 miRNAs. In alternative embodiments, the present invention relates to a method of treating and / or preventing cancer comprising targeting cancer stem cells by administering miRNAs which have increased expression levels in the cancer stem cells. Another aspect of the present invention relates to methods to enrich for a cancer stem cell population. Another aspect of the present invention relates to methods to identify miRNAs which contribute to the self-renewal capacity of cancer stem cells.

The invention provides methods for treating a patient with chronic lymphocytic leukemia of B cells (B-CLL). One method comprises administering to a patient with B-CLL, one or more benzamide derivatives, the benzamide derivatives including MS-275 and related compounds. Another method comprises administering to a patient with B-CLL, one or more of the benzamide derivatives, and additionally administering to the patient one or more antibodies immunospecific for 1D10 antigen. Additional methods for inducing apoptosis of B-CLL cells and for increasing expression of 1D10 antigen in B-CLL cells using the benzamide derivatives are also provided.

The present invention provides yeast cells that produce high concentrations of ethanol, culture media and bioreactors comprising the yeast cells, and methods for making and using the yeast cells in efficiently producing ethanol.

The present invention provides genetically modified strains of microorganisms that display enhanced tolerance to stress and / or inhibitors such as sodium acetate and vanillin. The enhanced tolerance can be achieved by increasing the expression of a protein of the Sm-like superfamily such as a bacterial Hfq protein and a fungal Sm or Lsm protein. Further, the present invention provides methods of producing alcohol from biomass materials by using the genetically modified microorganisms of the present invention.

Embodiments of the presently disclosed subject matter provide biomimetic cell culture substrates comprising highly tunable patterned polymer nanofiber matrices capable of modulating expression of critical self-renewal factors and markers of cell-cell interaction to maintain stemness of human mesenchymal stem cells in vitro. Embodiments of the presently-disclosed subject matter also provide scalable, highly repeatable methods of making biomimetic cell culture substrates by hot pressing thermoplastic polymer films into femtosecond laser-ablated nanopore molds to form patterned polymer nanofiber matrices on flat thermoplastic substrates.

A desired physiological state can be induced by altering the amount of gene products in target cells of a subject. The target cells are treated with at least one compound designed to reduce expression of at least one first gene by RNAi, and with at least one compound designed to increase expression from at least one second gene. The reduced expression of the first gene and the increased expression from the second gene in the target cells induces the desired physiological state in the subject. By altering target cell gene expression in this way, conditions such as angiogenesis or tumor growth and metastasis can be inhibited.

The disclosure relates to the fields of protein aggregation diseases including cancer. More specifically, it concerns a screening method for identifying compounds that inhibit or disrupt co-aggregation of one or more member proteins of a disease-related protein aggregome, in particular, a tumor-associated protein aggregome. Further, disclosed are agents and compounds identified by the screening method that can be applied to prevent or to treat protein aggregation diseases, such as cancer.

The invention relates to the field of online social interaction, in particular to a social interaction system based on a hand-held terminal. The social interaction system comprises a user register module, a location module, a contact person module, a virtual community module and an information transmission module, wherein the information transmission module is used for building communication between a user and an contact person in a contact person list and performing information transmission through an information transmission carrier, and is also used for building communication between contact persons in a virtual community and performing mutual information transmission through an information transmission carrier. According to the social interaction system, unexpected contact persons can be added through an adding manner of rubbed shoulders, so that the problem of the single communication target in the prior art is solved, expression mode and fun are improved during the communication of users which are contact persons of each other, the problem of simple and permanent communication modes is solved, the communication between an individual and a group is improved, the communication effect of the social interaction system is improved, and the problem of obstacles of early communication between strangers is solved, so that information transmission is accepted for the other person more easily and the communication effect of the social interaction system is improved.

The present invention relates to the diagnosis and treatment of vascular disorders, and to assays for the identification of agents which act upon the circulatory system. It is based, at least in part, on the identification of a novel mouse gene, termed Vezf1 (for "Vascular endothelial zinc finger 1"), which is expressed at higher levels during embryonic development of the circulatory system, in damaged blood vessels, and in newly formed blood vessels associated with tumor growth.

A transgenic plant transformed by a Protein Kinase Stress-Related Protein (PKSRP) coding nucleic acid, wherein expression of the nucleic acid sequence in the plant results in the plants's increased growth under normal or stress conditions and / or increased tolerance to environmental stress as compared to a wild type variety of the plant. Also provided are agricultural products, including seeds, produced by the transgenic plants. Also provided are isolated PKSRPs, and isolated nucleic acid coding PKSRPs, and vectors and host cells containing the latter.

The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Lepidoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic acid of the embodiments. These compositions find use in methods for controlling pests, especially plant pests.

Compositions for altering splicing activity of the DcpS gene and increasing SMN protein expression in target cells are provided. Also disclosed are methods of use of such compositions for the treatment of SMA.

Provided are improved methods using Glycogen synthase kinase 3 (GSK3) inhibitors by which endodermal cells, notably endodermal cells derived from human pluripotent stem cells (hPS), such as but not limited to hiPS-cells and hES-cells may be differentiated into hepatocyte like cells. The specific modulation of wingless integration gene (WNT)-signalling pathway and use of GSK3 inhibitors achieve direct differentiation and maturation of hepatocytes derived from human pluripotent stem (hPS) cells. GSK-3 inhibitors, when added to the growth medium at certain developmental stages, leads to more mature and functional features for the hepatocyte like cells as well as more pure and homogenous populations of hepatocyte like cells. Provided are also hepatocyte like cells obtained by these methods as well as compositions comprising them.

Aberrantly expressed piRNAs, genetically associated piRNAs and their relationship with cancer risk and severity are provided. Compositions and methods of using piRNA for treating cancer are provided. Methods of diagnosing subjects and determining the efficacy of active agents for treating cancer are also provided. Methods of correlating variant piRNA to cancer are also disclosed.

The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Coleoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic acid of the embodiments. These compositions find use in methods for controlling pests, especially plant pests.

Provided herein are methods and compositions related to nucleic acids encoding methylmalonyl-CoA mutase (MUT) as well as related vectors, such as AAV vectors and Anc80 vectors. Also, provided are methods for administering viral vectors that comprise a sequence that encodes an enzyme associated with an organic acidemia and an expression control sequence, in combination with synthetic nanocarriers coupled to an immunosuppressant.

The present invention relates to promoter variants in the form of an isolated polynucleotide comprising: i) a nucleotide sequence consisting of the DAS promoter sequence from Pichia or a functional part thereof, wherein the said DAS promoter is contained in SEQ ID NO: 1; and ii) at least one additional UAS, wherein the said UAS is comprised in SEQ ID NO: 2.

Provided herein is a combination comprising an HDAC inhibitor and an IMiD for increasing interferon regulated gene expression or decreasing c-MYC gene expression in a cancer cell or tumor in a subject in need thereof. Increasing interferon regulated gene expression may result in increased recognition of tumors by innate or adaptive immune system and an increase in programmed cell death (apoptosis) gene expression, increasing apoptosis in cancer cells and tumors. The cells can be multiple myeloma cells or diffuse large B-cell lymphoma cells. Also provided are methods for treating myelodysplastic syndromes / acute myeloid leukemia (MDS / AML) or pathogen infections in a subject in need thereof comprising administering to the subject an effective amount of HDAC inhibitor and an IMiD. The HDAC inhibitor can be an HDAC6-selective inhibitor.

The present invention relates to preventing and treating leukemia and diseases and disorders of the blood, by inhibiting canonical Wnt signaling in the osteoblasts. The inhibition is accomplished by blocking specific molecules and receptors in the pathway. The present invention also relates to a method of diagnosing leukemia and disorders of the blood, and methods and assay for drug screening and basic research.

The invention relates to the use of a composition comprising probiotic bacteria that regulate expression of key components involved in diet-induced insulin resistance for ameliorating or preventing diet-induced insulin resistance. The use of the probiotic strain and / or a fraction of said strain and / or metabolite of said strain for the manufacture of a medicament or a food or feed product to ameliorate diet-induced insulin resistance and help to obtain optimal body weight of a mammal is disclosed. Preferably, the composition comprises at least one probiotic Lactobacillus acidophilus strain and / or a fraction of said strain and / or metabolite of said strain for ameliorating or preventing diet-induced insulin resistance, said composition characterized by up-regulating expression of the ANGPTL4 gene encoding for FIAF in the intestine, down-regulating expression of the Elovl6 gene in the intestine as well as down-regulating expression of the SCD1 gene in skeletal muscles of a mammal, and wherein the probiotic strain is selected from the group of strains consisting of Lactobacillus acidophilus strain LA-5 (DSM13241).

The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Lepidoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic acid of the embodiments. These compositions find use in methods for controlling pests, especially plant pests.

The present invention provides methods and kits a) for preventing and / or treating cancer (e.g., colorectal cancer, neuroblastoma) that is linked, in part, to high levels of ODC activity and increased cellular polyamine content, b) for predicting cancer patient survival, especially cancer patient's whose cancer is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and c) for selecting the corresponding treatment options for such patients based on the allelic nucleotide sequence or SNP at positions +263 and / or +316 of the ODC1 gene as well as cancer treatment methods, in each case, which include the determination of the ODC1 genotype at the +263 and / or +316 positions, as a means to guide treatment selection.

The present invention relates to isolated nucleic acids encoding plant cyclotides. The invention also relates to the construction of a chimeric gene encoding all or a portion of the plant cyclotides, in sense or antisense orientation, wherein expression of the chimeric gene results in the production of altered levels of plant cyclotides in a transformed host cell.

The present invention provides a method and composition for treating a neurodegenerative disease. In particular, the present invention provides a method and composition to increase DJ-1 gene expression or DJ-1 protein activity to treat a neurodegenerative disease.